218 related articles for article (PubMed ID: 24463395)
1. 20S proteasome as novel biological target for organochalcogenanes.
Piovan L; Milani P; Silva MS; Moraes PG; Demasi M; Andrade LH
Eur J Med Chem; 2014 Feb; 73():280-5. PubMed ID: 24463395
[TBL] [Abstract][Full Text] [Related]
2. (77)Se and (125)Te NMR spectroscopy on a selectivity study of organochalcogenanes with L-amino acids.
Silva MS; Andrade LH
Org Biomol Chem; 2015 Jun; 13(21):5924-9. PubMed ID: 25923042
[TBL] [Abstract][Full Text] [Related]
3. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome].
Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH
Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029
[TBL] [Abstract][Full Text] [Related]
4. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
10. C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
Hovhannisyan A; Pham TH; Bouvier D; Qin L; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2013 May; 23(9):2696-703. PubMed ID: 23541650
[TBL] [Abstract][Full Text] [Related]
11. Cupriphilic compounds to aid in proteasome inhibition.
Mukherjee S; Sparks R; Metcalf R; Brooks W; Daniel K; Guida WC
Bioorg Med Chem Lett; 2016 Aug; 26(15):3826-9. PubMed ID: 27311892
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
[TBL] [Abstract][Full Text] [Related]
13. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
14. New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.
Neilsen PM; Pehere AD; Pishas KI; Callen DF; Abell AD
ACS Chem Biol; 2013 Feb; 8(2):353-9. PubMed ID: 23190346
[TBL] [Abstract][Full Text] [Related]
15. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
17. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
18. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
19. α- and β-hydrazino acid-based pseudopeptides inhibit the chymotrypsin-like activity of the eukaryotic 20S proteasome.
Bordessa A; Keita M; Maréchal X; Formicola L; Lagarde N; Rodrigo J; Bernadat G; Bauvais C; Soulier JL; Dufau L; Milcent T; Crousse B; Reboud-Ravaux M; Ongeri S
Eur J Med Chem; 2013; 70():505-24. PubMed ID: 24185380
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
